New drug cocktail aims to tame tough lymphoma
NCT ID NCT05615636
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell lymphoma that has not responded to prior treatments. The goal is to see if this mix can shrink tumors or stop the cancer from growing. About 36 adults with follicular lymphoma or diffuse large B-cell lymphoma will take part. The approach is not a cure but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.